启动抗TNF或免疫调节剂后继续使用5ASA在IBD中无获益:一项基于人群的研究
该回顾性队列研究利用马尼托巴大学IBD流行病学数据库(1996-2018年处方数据),评估5ASA使用者在启动抗TNF或免疫调节剂后继续 versus 停用5ASA的结局。结果显示,在UC或CD中,继续使用5ASA与停用者在住院、手术、激素启用、结直肠癌或药物相关不良事件方面均无差异。结论认为,一旦启动抗TNF或免疫调节剂,继续5ASA似乎无额外获益。
要点
- 5ASA在IBD中仍常见处方,但UC中持续使用率低。
- 启动抗TNF或免疫调节剂后继续5ASA未见额外获益。
- 5ASA使用模式以间歇性为主(65.1%)。
核心结论
- 在IBD患者中,一旦启动抗TNF或免疫调节剂,继续使用5ASA似乎不增加获益。
研究设计与样本
- 回顾性队列研究,使用基于人群的马尼托巴大学IBD流行病学数据库,纳入1996年至2018年的处方配药数据。
主要发现
- 8379例(77%)IBD患者至少接受过一次5ASA配药(UC为85%,CD为68%)。
- 5ASA最常见使用模式为间歇性(65.1%),一次性为4.1%,既往连续为13.8%,持续为17%。
- 总IBD人群中,口服5ASA占59%,直肠给药占3%,联合给药占14%。
- 所有5ASA起始者中,仅25%持续使用超过20个月。
- 启动免疫调节剂或抗TNF后,UC或CD中继续与停用5ASA者在住院、手术、激素启用、结直肠癌或药物相关不良事件方面无差异。
临床怎么用
- 对于已启动抗TNF或免疫调节剂的IBD患者,可考虑停用5ASA以避免不必要的用药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the advent of biological therapy in IBD, it is uncertain to what extent 5aminosalicylates (5ASA) are used. AIMS: To explore whether or not 5ASA is continued once biological or immunomodulator therapy is initiated, and the outcomes in those who continued the 5ASAs. METHODS: We conducted a retrospective cohort study using the population-based University of Manitoba IBD Epidemiologic Database which includes prescription drug dispensation from 1996 through 2018. We assessed outcomes among 5ASA users who continued versus discontinued 5ASA after initiation of anti-TNF therapy or immunomodulators. RESULTS: In all, 8379 (77%) of persons with IBD received at least one 5ASA dispensation (85% of ulcerative colitis, UC and 68% of Crohn's disease, CD). There was a reduction in later years, particularly for CD. The most common pattern of 5ASA use was intermittent at 65.1% (stopping and restarting use) versus one-time (4.1%), previous continuous (13.8%) and persistent (17%). Among the total IBD population use was 59% oral, 3% rectal and 14% combination. Of all 5ASA starts, only 25% were continued longer than 20 months. After immunomodulator or anti-TNF initiation, there was no difference in either UC or CD for negative outcomes (hospitalisation, surgery, corticosteroid starts, colorectal cancers or drug-related adverse events) between those who continued 5ASA versus those who discontinued. CONCLUSIONS: 5ASA remains commonly prescribed in UC and CD. Rates of persistent use in UC are low. Once an anti-TNF or immunomodulator is initiated, continuation of 5ASA seems to add no benefit.
引用
- Bernstein CN, Tenakoon A, Singh H, et al. Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study. Aliment Pharmacol Ther. 2021. PMID: 34247410. doi:10.1111/apt.16518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。